Aegerion underwriters exercise over-allotment option

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions. 

Including the over-allotment shares, a total of 5,750,000 shares will have been sold in the offering, resulting in net proceeds of approximately $48.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.

The joint book-running managers of the initial public offering were Leerink Swann LLC and Lazard Capital Markets LLC. The co-managers were Needham & Company, LLC, Canaccord Genuity Inc. and Collins Stewart LLC.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on October 22, 2010.


Aegerion Phamaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study examines the impacts of racism on physical and mental well-being of Black people